This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival.
Heartfailure (HF) is a complex syndrome which leads to significant morbidity and mortality, poor quality of life and extremely high costs to healthcare systems worldwide.
‘Real knowledge is to know the extent of one’s ignorance ’ Confucius This editorial refers to ‘Gaps in knowledge and management of iron deficiency in heartfailure: a nationwide survey of cardiologists in China’, by Su et al.
Stem cell-based therapy improved quality of life for patients with advanced heartfailure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial.
Despite proven benefits in reducing morbidity and mortality, many heartfailure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). ESC HeartFailure 2024; 11 : 560–569. The post Digital Consults to Enhance HeartFailure Treatment: The ADMINISTER Trial appeared first on Cardiology Update.
RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heartfailure hospitalizations and improves quality of life vs optimal medical therapy alone.
We hope to identify high-risk patients for early intervention to reduce the incidence of HF and improve their quality of life. This online forecasting tool not only processes a large amount of data but also continuously optimizes and adjusts the accuracy of the model according to the latest medical research and clinical data.
milla1cf Tue, 05/28/2024 - 07:00 May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heartfailure, according to research presented at HeartFailure 2024 , a scientific congress of the European Society of Cardiology (ESC).
In patients with obesity and heartfailure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heartfailure events, based on findings from the SUMMIT trial.
Although heartfailure prognosis is grim, the ALT-FLOW trials two year results suggest that diverting blood from the left atrium to the coronary sinus using a shunt could have lasting benefits for patients with HFmrEF/HFpEF.
In the ABYSS trial, the cardiovascular safety of interrupting beta-blocker could not be shown in comparison with beta-blocker continuation and beta-blocker interruption did not improve quality of life.
It can be associated with reduced quality of life and complications such as heartfailure and stroke. Atrial fibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
Barostim is the world’s first FDA-approved neuromodulation heartfailure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. I felt weak and tired all the time and knew I didn’t want to spend my life sitting in the living room chair. and Allina Health.
ABSTRACT Aims Heartfailure outcomes remain poor despite advances in therapy. The European Society of Cardiology HeartFailure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Chronic heartfailure (CHF) combined with depression represents a significant clinical challenge due to the mutual exacerbation of physical and psychological symptoms. Outcomes were assessed by evaluating the clinical efficacy, cardiac function, inflammatory markers, depressive symptoms, and quality of life.
The AccuCinch® System, utilized by Allegheny General Hospital, offers a breakthrough approach to treating heartfailure by targeting the left ventricle.
RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heartfailure events or improve quality of life in heartfailure patients with a preserved ejection fraction (HFpEF). For more information: www.corviamedical.com If you enjoy this content, please share it with a colleague
Studies estimate that severe regurgitation occurs in up to 4% of individuals 75 and older and is often linked with conditions like heartfailure, atrial fibrillation or pulmonary hypertension. We prioritize improving quality of life, particularly for patients experiencing severe fatigue and breathlessness.
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heartfailure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
Heartfailure (HF) is recognized as an epidemic in the contemporary world, impacting around 1%–2% of the adult population and affecting around 6 million Americans. HF remains a major cause of mortality, morbidity, and poor quality of life.
This study found that treatment with sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with heartfailure and reduced ejection fractions (HFrEF) was associated with lower skeletal muscle pathology. Muscle biopsies were collected from patients treated with SGLT2 inhibitors (>12 months) and compared to untreated controls.
Heartfailure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.
Iron deficiency (ID) is a common comorbidity among patients with heartfailure (HF), and it is associated with reduced exercise tolerance and quality of life and serves as a marker of increased risk of hospitalizations and mortality.
However, there is a notable gap in device options for infants and young children with end stage heartfailure. Although tools for the youngest heart patients are limited, the Ochsner Children’s Hospital team provides top-of-the-line care to bridge patients safely to transplant and a hope for a better quality of life.
Heartfailure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
Heartfailure is a major health concern, especially for aging populationsit significantly increases mortality rates, and severely impacts quality of life of those affected. Exercise therapy has been shown to be particularly effective for patients with heartfailure.
Background Exercise training is commonly employed as a efficacious supplementary treatment for individuals suffering from heartfailure, but the optimal exercise regimen is still controversial. 41.70), and Minnesota Living with HeartFailure Questionnaire (MD = −4.45, 95% CI for −6.25 to −2.64) compared to MICT.
In this episode, Andrea Price, MS, AACC hosts Jae Patton, MSN, CRNP, AACC and Sarah Godfrey, MD, MPH to share insights for ensuring quality of life when time is short: tools for the end-stage heartfailure care.
Circulation: HeartFailure, Ahead of Print. Compared with cold and wet patients, cold and dry patients also had better baseline functional capacity and quality of life and experienced milder improvements after LVAD: EuroQol (+0.11 versus +0.17;P=0.001),
Refractory heartfailure (RHF), or end-stage heartfailure, has a poor prognosis and high case fatality rate, making it one of the therapeutic difficulties in the cardiovascular field.
This study aimed to evaluate the cost-effectiveness of digoxin versus beta-blockers for heart rate control in patients with permanent AF and symptoms of heartfailure. Background Atrial fibrillation (AF) is a major and increasing burden on health services.
Hashtag: #ESCPrev2025 HeartFailure 2025 Date: Saturday, 17 May – Tuesday, 20 May 2025 Location: Belgrade, Serbia Overview: The HeartFailure Congress stands as the premier global gathering encompassing the full spectrum of heartfailure.
Publication date: Available online 29 December 2023 Source: The American Journal of Cardiology Author(s): Lorenzo Braghieri, Arwa Younis, Chadi Tabaja, Pasquale Santangeli, Tyler Taigen, Walid I. Saliba, Oussama M. Wazni, Ayman A.
Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heartfailure patients, reducing mortality rise and improving quality of life.
ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heartfailure (HF).MethodsFrom and improved patients’ quality of life scores.
12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heartfailure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.
Background Atrial fibrillation (AF) is common in individuals with heartfailure (HF). Individuals with HF and AF may have a reduced functional capacity and quality of life (QoL) which leads to hospital admission and burden on clinical services. Evidence supported the effect of exercise training in individuals with HF.
Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,
Guideline-directed medical therapies and guideline-directed nonpharmacological therapies improve quality of life and survival in patients with heartfailure (HF), but eligible patients, particularly women and individuals from underrepresented racial and ethnic groups, are often not treated with these therapies.
In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. The late breaking research was presented by principal investigator Martin S. Cytokinetics Inc. provided the funding for this study.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content